Sinphar Pharmaceutical Co (TPE:1734) Total Operating Expense: NT$1,077 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1734 Sinphar Pharmaceutical Co Ltd TPE:1734
80 GF Score
Price NT$31.75
GF Value NT$31.33
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Sinphar Pharmaceutical Co Total Operating Expense?

Sinphar Pharmaceutical Co TPE:1734 +0.16% 80 Total Operating Expense is NT$1,077 Mil as of Mar. 2026. GuruFocus rates TPE:1734 with a GF Score™ of 80/100 and a GF Value™ of NT$31.33 (Fairly Valued). The stock has 1 warning sign investors should review.

Sinphar Pharmaceutical Co's Total Operating Expense for the three months ended in Mar. 2026 was NT$271 Mil. Sinphar Pharmaceutical Co's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was NT$1,077 Mil.

Sinphar Pharmaceutical Co Total Operating Expense Related Terms

Sinphar Pharmaceutical Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co Total Operating Expense Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,068.94 893.50 803.51 943.01 1,040.03

Sinphar Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.15 245.85 273.62 286.42 271.11
TPE:1734
80GF Score
Sinphar Pharmaceutical Co Ltd TPE:1734
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinphar Pharmaceutical Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,077 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of NT$1,077 Mil mean?
Sinphar Pharmaceutical Co (TPE:1734) has a Total Operating Expense of NT$1,077 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sinphar Pharmaceutical Co and its competitors.
Is Sinphar Pharmaceutical Co's Total Operating Expense too high?
Sinphar Pharmaceutical Co's current Total Operating Expense is NT$1,077 Mil. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Total Operating Expense compare to VRTX and REGN?
Sinphar Pharmaceutical Co's Total Operating Expense of NT$1,077 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current Total Operating Expense is NT$1,077 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.33, compared to a current price of NT$31.75 — trading 1.3% above its estimated fair value. The current Total Operating Expense is NT$1,077 Mil. Sinphar Pharmaceutical Co's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Total Operating Expense is NT$1,077 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be overvalued. The current stock price of NT$31.75 is trading 1.3% above its estimated GF Value™ of NT$31.33. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

  • Total Operating Expense: NT$1,077 Mil
  • GF Value™: NT$31.33 vs. price of NT$31.75 (1.3% above fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinphar Pharmaceutical Co Business Description

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
80GF Score

Get the complete analysis for TPE:1734

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.75
Price
NT$31.33
GF Value